Novel human multiple myeloma cell line UHKT-893

Uherková, Lenka; Vančurová, Irena; Vyhlídalová, Ilona; Pleschnerová, Markéta; Špıčka, Ivan; Mihalová, Romana; Březinová, Jana; Hodný, Zdeněk; Čermáková, Kamila; Polanská, Veronika; Marinov, Iuri; Jedelský, Petr; Kuželová, Kateřina; Stöckbauer, Petr

doi:10.1016/j.leukres.2012.12.004

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Till now, 29% and 8% of plasma cell‐derived cell lines have been established with dependence on IL‐6 or on stroma cells, respectively. IL‐6 has been found to be nearly the only cytokine these cell lines are dependent on . In accordance with this finding, IL‐6 was found to be essential for both survival and growth of UHKT‐944 cells.…”

Section: Discussionsupporting

confidence: 67%

“…Mass spectrometry MALDI‐TOF was employed to analyze two selected protein spots from a two‐dimensional (2D) electrophoresis gel of whole‐cell lysate of UHKT‐944 cells after standard in‐gel digestion. Protein spots were selected based on the comparison with protein map of UHKT‐893 cell line, which was established in our laboratory in the same year as UHKT‐944 . One of the protein spots was chosen owing to the high protein expression in UHKT‐944 cells, and its absence in UHKT‐893 protein map.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of a new human plasma cell leukemia cell line UHKT‐944

Vyhlídalová

Uherková

Pleschnerová

et al. 2015

European J of Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Methodsmentioning

confidence: 99%

Characterization of a new human plasma cell leukemia cell line UHKT‐944

Vyhlídalová

Uherková

Pleschnerová

et al. 2015

European J of Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique

Glukhova¹,

Prusakova²,

Trizna³

et al. 2016

CPD

View full text Add to dashboard Cite

Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.

show abstract

Novel human multiple myeloma cell line UHKT-893

Cited by 2 publications

References 20 publications

Characterization of a new human plasma cell leukemia cell line UHKT‐944

Characterization of a new human plasma cell leukemia cell line UHKT‐944

Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique

Contact Info

Product

Resources

About